Safety and Efficacy of Antiviral Therapy for Prevention of Cytomegalovirus Reactivation in Immunocompetent Critically Ill Patients: A Randomized Clinical Trial.

ABSTRACT:

Importance

Latent cytomegalovirus (CMV) infection is present in more than half the adult population, and a viral reactivation (ie, when the virus becomes measurable in body fluids such as blood) can occur in up to one-third of these individuals during episodes of critical illness.

Objective

To determine whether antiviral therapy is safe and effective for preventing CMV reactivation in a general population of critically ill patients.

Design, setting, and participants

A single-center, open-label, randomized, controlled clinical trial recruited 124 CMV-seropositive patients undergoing mechanical ventilation for at least 24 hours in the intensive care unit between January 1, 2012, and January 31, 2014. The mean baseline Acute Physiology and Chronic Health Evaluation II sc

SUBMITTER: Cowley NJ 

PROVIDER: S-EPMC5818821 | biostudies-literature | 2017 Jun

REPOSITORIES: biostudies-literature